Amgen patents on Repatha invalid, judge rules in reversal

The decision by Judge Richard Andrews overturns a February jury verdict that affirmed two patents held by Amgen on the cholesterol drug.

By Ned Pagliarulo • Aug. 28, 2019

Immatics shows Celgene isn't done stocking cell therapy pipeline

As its takeover by Bristol-Myers nears closing, Celgene is committing $75 million to research into T-cell redirecting technology.

By Jonathan Gardner • Aug. 28, 2019

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff